- $329.81m
- $36.76m
- 55
- 42
- 14
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.11 | ||
| Price to Tang. Book | 1.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.96% | ||
| Return on Equity | -12.77% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 12 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. It is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.
Directors
- Francois Nader NEC (64)
- Scott Requadt PRE (53)
- Mary Kay Fenton CFO (57)
- Michael Zdanowski CTO (54)
- Suzanne Ildstad CSO (68)
- Nancy Krieger OTH (54)
- Geoff MacKay DRC (54)
- Sandip Agarwala IND (41)
- Nicholas Galakatos IND (63)
- Mark McDade IND (65)
- Gaurav Shah IND (46)
- Sapna Srivastava IND (50)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 15th, 2002
- Public Since
- May 7th, 2021
- No. of Employees
- 44
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 25,646,509
- Address
- 27 West 24th Street, Suite 702, NEW YORK, 10010
- Web
- https://www.tourmalinebio.com/
- Phone
- +1 3026365400
- Auditors
- Deloitte & Touche LLP
Upcoming Events for TRML
Q3 2024 Tourmaline Bio Inc Earnings Release
Similar to TRML
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Tourmaline Bio share price?
As of Today at 23:48 UTC, shares in Tourmaline Bio are trading at $15.30. This share price information is delayed by 15 minutes.
How has the Tourmaline Bio share price performed this year?
Shares in Tourmaline Bio last closed at $15.30 and the price had moved by +27.57% over the past 365 days. In terms of relative price strength the Tourmaline Bio share price has outperformed the S&P500 Index by +1.51% over the past year.
What are the analyst and broker recommendations for Tourmaline Bio?
The overall consensus recommendation for Tourmaline Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Tourmaline Bio dividend yield?
Tourmaline Bio does not currently pay a dividend.
Does Tourmaline Bio pay a dividend?
Tourmaline Bio does not currently pay a dividend.
When does Tourmaline Bio next pay dividends?
Tourmaline Bio does not currently pay a dividend.
How do I buy Tourmaline Bio shares?
To buy shares in Tourmaline Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tourmaline Bio?
As of the previous close price of $15.30, shares in Tourmaline Bio had a market capitalisation of $392.39m.
Where are Tourmaline Bio shares listed?
Here are the trading details for Tourmaline Bio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TRML
What kind of share is Tourmaline Bio?
Based on an overall assessment of its quality, value and momentum Tourmaline Bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tourmaline Bio share price forecast for 2024?
The analyst consensus target price for shares in Tourmaline Bio is $58.33. That is 281.24% above the last closing price of $15.30.
Analysts covering Tourmaline Bio currently have a consensus Earnings Per Share (EPS) forecast of -$2.92 for the next financial year.
What is the trend in the Tourmaline Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tourmaline Bio. Over the past six months, its share price has underperformed the S&P500 Index by -43.35%.
As of the last closing price of $15.30, shares in Tourmaline Bio were trading -29.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tourmaline Bio PE Ratio?
The Tourmaline Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tourmaline Bio?
Tourmaline Bio's management team is headed by:
- Francois Nader - NEC
- Scott Requadt - PRE
- Mary Kay Fenton - CFO
- Michael Zdanowski - CTO
- Suzanne Ildstad - CSO
- Nancy Krieger - OTH
- Geoff MacKay - DRC
- Sandip Agarwala - IND
- Nicholas Galakatos - IND
- Mark McDade - IND
- Gaurav Shah - IND
- Sapna Srivastava - IND